NCT07554079

Brief Summary

Long-bone fractures, particularly of femur and tibia, are common following fall injury and road traffic accidents.1,2 The standard treatment is "intramedullary nailing," where a metal rod is inserted into the center of the bone to hold it in place.3,4 However, surgical site infection (SSI) and fracture related infection (FRI) remain significant complications of nailing that delay healing and increase healthcare costs.5,6 To prevent these infections, doctors give patients antibiotics around the time of surgery. However, there is ongoing debate about how long these antibiotics should be continued. In many regions, patients receive antibiotics for several days, but recent evidence suggests that a shorter course may be just as effective and could reduce the risk of antibiotic resistance and side effects. Study Question The goal of this study is to determine if a one-day (short) course of antibiotics is as effective as a three-day (standard) course in preventing infections after bone-nailing surgery. Hypotheses Null Hypothesis (H0): There is no significant difference in the incidence of infection or short-term clinical outcomes between the one-day (short-course) and three-day (standard-course) antibiotic protocols. Alternative Hypothesis (H1): There is a significant difference in the incidence of infection or short-term clinical outcomes between the one-day (short-course) and three-day (standard-course) antibiotic protocols.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
56

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Feb 2024

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

February 15, 2024

Completed
1.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 8, 2025

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

November 8, 2025

Completed
5 months until next milestone

First Submitted

Initial submission to the registry

April 21, 2026

Completed
7 days until next milestone

First Posted

Study publicly available on registry

April 28, 2026

Completed
Last Updated

May 4, 2026

Status Verified

April 1, 2026

Enrollment Period

1.7 years

First QC Date

April 21, 2026

Last Update Submit

April 28, 2026

Conditions

Keywords

AntibioticAntimicrobial StewardshipOrthopedicsSurgical Site Infection

Outcome Measures

Primary Outcomes (1)

  • Incidence of Wound Infection based on ASEPSIS score

    The primary outcome is the rate of wound infection as categorized by the ASEPSIS scoring system. The ASEPSIS score is a validated tool that evaluates wound healing based on clinical criteria (Additional treatment, Serous discharge, Erythema, Purulent exudate, Separation of deep tissues, Isolation of bacteria, and Stay as inpatient). Satisfactory Healing: Score 0-10 Disturbance in Healing: Score 11-20 Infection: Score \>20 The primary comparison will be the proportion of patients in each group reaching the "Wound Infection" category.

    From enrollment to the end of postoperative follow up at six week

Study Arms (2)

Standard Course Antibiotics

ACTIVE COMPARATOR

Nine postoperative doses of cefuroxime 750 mg; each dose every eight hours for three days

Drug: Standard Course Antibiotics

Short Course Antibiotics

EXPERIMENTAL
Drug: Short Course Antibiotics

Interventions

Three postoperative doses of cefuroxime 750 mg; each dose eight hours apart

Short Course Antibiotics

Nine postoperative doses of cefuroxime 750 mg; each dose eight hours apart

Standard Course Antibiotics

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Adult patients (≥18 years)
  • Diaphyseal fractures of the femur (AO 32) or tibia (AO 42), including closed injuries and Gustilo-Anderson type I open fractures, who were scheduled for intramedullary interlocking nailing

You may not qualify if:

  • Polytrauma
  • Open fractures classified as Gustilo-Anderson type II or III
  • Procedures other than intramedullary nailing
  • Pregnancy
  • Comorbidities known to affect infection risk, such as diabetes mellitus, immunocompromised states, chronic steroid use, active skin or chest infections, or other conditions requiring alternative antibiotic regimens

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Dhulikhel Hospital, Kathmandu University Hospital

Dhulikhel, Bagmati, Nepal

Location

Related Publications (3)

  • Rodrigues FL, Ferrari ALM, Faria FF, Pinto RLE, Lopes MF, Santos MEA, Varela EC, Lopes Filho MJ, Cecyn MN, De Oliveira NHC. Epidemiology and Outcomes of Intramedullary Nailing for Tibial Diaphyseal Fractures: A Retrospective Multicenter Cohort Study. Cureus. 2025 Apr 24;17(4):e82894. doi: 10.7759/cureus.82894. eCollection 2025 Apr.

    PMID: 40416276BACKGROUND
  • Saleeb H, Tosounidis T, Papakostidis C, Giannoudis PV. Incidence of deep infection, union and malunion for open diaphyseal femoral shaft fractures treated with IM nailing: A systematic review. Surgeon. 2019 Oct;17(5):257-269. doi: 10.1016/j.surge.2018.08.003. Epub 2018 Aug 27.

    PMID: 30166239BACKGROUND
  • GBD 2019 Fracture Collaborators. Global, regional, and national burden of bone fractures in 204 countries and territories, 1990-2019: a systematic analysis from the Global Burden of Disease Study 2019. Lancet Healthy Longev. 2021 Sep;2(9):e580-e592. doi: 10.1016/S2666-7568(21)00172-0.

    PMID: 34723233BACKGROUND

MeSH Terms

Conditions

Femoral FracturesTibial FracturesSurgical Wound Infection

Condition Hierarchy (Ancestors)

Fractures, BoneWounds and InjuriesLeg InjuriesWound InfectionInfectionsPostoperative ComplicationsPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor

Study Record Dates

First Submitted

April 21, 2026

First Posted

April 28, 2026

Study Start

February 15, 2024

Primary Completion

November 8, 2025

Study Completion

November 8, 2025

Last Updated

May 4, 2026

Record last verified: 2026-04

Locations